• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Childbirth without fear in case of Von Willebrand's disease].

作者信息

Cornuz J, Knecht H, Delaloye J F, Bossart H, Bachmann F

机构信息

Département de gynécologie et d'obstétrique, Centre hospitalier universitaire vaudois, Lausanne.

出版信息

Schweiz Med Wochenschr. 1993 Jan 23;123(3):76-9.

PMID:8426951
Abstract

We report two cases of von Willebrand (type I) disease with vWF antigen levels of 21 and 25%, vWF ristocetin cofactor concentrations of 32 and 30%, and coagulation FVIII levels of 10 and 50% respectively. Template bleeding times were 20 and 11 minutes respectively. Both of these women exhibited a progressive and marked improvement of the vWF/FVIII complex during pregnancy. In the first, all parameters had completely normalized in the 37th week when a cesarean section was performed without hemorrhagic complications. The second case had borderline normal levels of the vWF/FVIII complex in the 37th week and underwent normal delivery in the 39th week. The improvement persisted for at least one week post-partum and in the first case values were still higher 10th weeks after delivery than they had been prior to the pregnancy. These observations and similar cases in the recent literature suggest that obstetrical operations and normal delivery are not associated with major blood losses in cases of moderately severe vWD of type I. These patients probably will not need vWF/FVIII concentrates for adequate hemostasis.

摘要

相似文献

1
[Childbirth without fear in case of Von Willebrand's disease].
Schweiz Med Wochenschr. 1993 Jan 23;123(3):76-9.
2
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.对血管性血友病患者持续输注凝血因子 VIII - 血管性血友病因子(vWF)联合浓缩物(海莫莱士)的安全性和有效性。
Thromb Haemost. 1999 Feb;81(2):229-33.
3
Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.两种血管性血友病因子浓缩物[Biostate和AHF(高纯度)]在血管性血友病患者中的药代动力学比较。一项随机交叉、多中心研究。
Thromb Haemost. 2007 Jun;97(6):922-30.
4
Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.血管性血友病因子/凝血因子VIII浓缩物的比较分析与分类:对血管性血友病患者治疗的影响
Semin Thromb Hemost. 2006 Sep;32(6):626-35. doi: 10.1055/s-2006-949668.
5
Pregnancy in type 2B VWD: a case series.2B 型血管性血友病患者的妊娠:病例系列研究。
Haemophilia. 2012 May;18(3):406-12. doi: 10.1111/j.1365-2516.2011.02691.x. Epub 2011 Nov 14.
6
[Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].2B型血管性血友病患者分娩期及产褥期的管理
Z Geburtshilfe Neonatol. 2002 Jul-Aug;206(4):151-5. doi: 10.1055/s-2002-33670.
7
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.静脉注射去氨加压素和因子VIII-血管性血友病因子浓缩物用于治疗和预防1型、2型和3型血管性血友病患者的出血。
Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399.
8
Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.血管性血友病因子/凝血因子VIII浓缩物在血管性血友病治疗中的应用
Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570.
9
von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.不同纯度的凝血因子 VIII 浓缩物中所含的血管性血友病因子支持来自异质性血管性血友病患者组的血样中的血小板黏附。
Haematologica. 1998 Nov;83(11):1009-14.
10
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.在手术环境中使用去氨加压素和血管性血友病因子-凝血因子VIII浓缩物治疗1型、2型和3型血管性血友病患者。
Acta Haematol. 2009;121(2-3):167-76. doi: 10.1159/000214857. Epub 2009 Jun 8.